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Systems/Circuits
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on
Energy Balance
David J. Reiner,1* Elizabeth G. Mietlicki-Baase,1* Lauren E. McGrath,1 Derek J. Zimmer,1,2 Kendra K. Bence,2
Gregory L. Sousa,1,2 Vaibhav R. Konanur,3 X Joanna Krawczyk,1 David H. Burk,4 Scott E. Kanoski,3
X Gerlinda E. Hermann,4 Richard C. Rogers,4 and Matthew R. Hayes1
1Translational Neuroscience Program, Department of Psychiatry, Perelman School of Medicine, and 2Department of Animal Biology, School of Veterinary
Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, 3Department of Biological Sciences, Human and Evolutionary Biology Section,
University of Southern California, Los Angeles, California 90089, and 4Pennington Biomedical Research Center, Louisiana State University, Baton Rouge,
Louisiana 70808
Astrocytes are well established modulators of extracellular glutamate, but their direct influence on energy balance-relevant behaviors is
largely understudied. As the anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are partly mediated by central
modulation of glutamatergic signaling, we tested the hypothesis that astrocytic GLP-1R signaling regulates energy balance in rats. Central
or peripheral administration of a fluorophore-labeled GLP-1R agonist, exendin-4, localizes within astrocytes and neurons in the nucleus
tractus solitarius (NTS), a hindbrain nucleus critical for energy balance control. This effect is mediated by GLP-1R, as the uptake of
systemically administered fluorophore-tagged exendin-4 was blocked by central pretreatment with the competitive GLP-1R antagonist
exendin-(9 –39). Ex vivo analyses show prolonged exendin-4-induced activation (live cell calcium signaling) of NTS astrocytes and
neurons; these effects are also attenuated by exendin-(9 –39), indicating mediation by the GLP-1R. In vitro analyses show that the
application of GLP-1R agonists increases cAMP levels in astrocytes. Immunohistochemical analyses reveal that endogenous GLP-1 axons
form close synaptic apposition with NTS astrocytes. Finally, pharmacological inhibition of NTS astrocytes attenuates the anorectic and
body weight-suppressive effects of intra-NTS GLP-1R activation. Collectively, data demonstrate a role for NTS astrocytic GLP-1R signal-
ing in energy balance control.
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Introduction
The nucleus tractus solitarius (NTS) of the caudal brainstem is a
critical nucleus in the regulation of energy balance. The NTS acts
as a sensor for circulating neuroendocrine factors important for
the control of food intake and is the first nucleus within the brain
to receive and process vagally mediated satiation signals arising
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Significance Statement
Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce food intake and are approved by the Food and Drug Administration
for the treatment of obesity, but the cellular mechanisms underlying the anorectic effects of GLP-1 require further investigation.
Astrocytes represent a major cellular population in the CNS that regulates neurotransmission, yet the role of astrocytes in medi-
ating energy balance is largely unstudied. The current data provide novel evidence that astrocytes within the NTS are relevant for
energy balance control by GLP-1 signaling. Here, we report that GLP-1R agonists activate and internalize within NTS astrocytes,
while behavioral data suggest the pharmacological relevance of NTS astrocytic GLP-1R activation for food intake and body weight.
These findings support a previously unknown role for CNS astrocytes in energy balance control by GLP-1 signaling.
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from the gastrointestinal (GI) tract (Grill and Hayes, 2012). The
NTS is therefore well positioned as a key hub to combine a variety
of feeding-related signals, and to transmit this integrated infor-
mation to downstream nuclei to influence overall energy balance
control (Grill and Hayes, 2009). Within the NTS, the incretin
hormone glucagon-like peptide-1 (GLP-1) acts to control food
intake and body weight (Grill and Hayes, 2012; Hayes et al.,
2014). Produced peripherally by intestinal L cells and centrally by
preproglucagon (PPG) neurons within the caudal NTS, GLP-1
and GLP-1 receptor (GLP-1R) agonists suppress food intake and
body weight through direct GLP-1R signaling in the NTS, as well
as through action in other distributed nuclei in the brain (McMa-
hon and Wellman, 1998; Grill and Hayes, 2009; Dossat et al.,
2011; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013, 2014;
Rupprecht et al., 2013; Alhadeff et al., 2014; Secher et al., 2014;
Hsu et al., 2015). However, the cellular and molecular mecha-
nisms mediating the energy balance effects of GLP-1R activation
remain largely underinvestigated. GLP-1R agonists such as
exendin-4 (Ex-4) and liraglutide are widely used in the treatment
of type 2 diabetes mellitus (T2DM; Hayes et al., 2014), and lira-
glutide was recently approved by the Food and Drug Administra-
tion (FDA) for the treatment of obesity (Tella and Rendell, 2015).
These important medical applications of GLP-1R agonists high-
light the urgent need to understand more fully the mechanisms
by which GLP-1R activation impacts physiology and behavior,
including the control of feeding and body weight.
Vagal afferents synapsing in the NTS, as well as NTS PPG
neurons themselves, are glutamatergic (Ritter, 2004; Grill and
Hayes, 2012; Zheng et al., 2015). Thus, recent attention has fo-
cused on the role of glutamatergic signaling in mediating the
anorexigenic effects of central GLP-1R activation. In particular,
several studies demonstrate a role for the ionotropic AMPA/kai-
nate glutamate receptors (Hisadome et al., 2011; Mietlicki-Baase
et al., 2013; Mietlicki-Baase et al., 2014) as downstream mediators
of the food intake- and body weight-suppressive effects of
GLP-1R signaling within midbrain and forebrain nuclei. Impor-
tantly, these reports also indicate that the relevant GLP-1Rs are
located presynaptically to AMPA/kainate receptors and can in-
fluence presynaptic glutamate release (Acuna-Goycolea and van
den Pol, 2004; Amato et al., 2010; Hisadome et al., 2011;
Mietlicki-Baase et al., 2013, 2014). However, to date, the ability of
GLP-1R activation to affect energy balance via non-neuronal
modulation of synaptic glutamatergic signaling has not been sys-
tematically evaluated.
Most studies of the central control of energy balance have
focused on the actions of neurons, but astrocytes represent an-
other key CNS cell population that modulates glutamatergic
neurotransmission, thereby potentially influencing behavior
(Scofield and Kalivas, 2014; Yang et al., 2015). Indeed, glutamate
is predominately cleared from the synapse by the following two
subtypes of astrocytic glutamate reuptake transporters: gluta-
mate transporter-1 (GLT-1) and glutamate aspartate transporter
(GLAST; Perego et al., 2000; Danbolt, 2001). Intriguingly, a small
body of literature suggests that astrocytes within the CNS express
the GLP-1R (Chowen et al., 1999; Iwai et al., 2006; Kobayashi et
al., 2013), yet no studies have systemically examined its expres-
sion or behavioral relevance for energy balance control. As the
NTS expresses GLP-1R (Hayes et al., 2010; Hayes, 2012) and is
the first central site to receive and process within-meal vagally
mediated glutamatergic signals arising from the GI tract (Moran,
2006; Grill and Hayes, 2009), a combination of in vitro, ex vivo,
and in vivo techniques was used to test the hypothesis that




Male Sprague Dawley rats (weight, 320 – 420 g; Charles River Laborato-
ries) individually housed in hanging wire cages maintained at 23°C with
a 12 h light/dark cycle were used for the majority of these studies. For the
live cell calcium imaging studies, male Long–Evans rats (weight, 250 –300
g; from a breeding colony at Pennington Biomedical Research Center)
were used. All procedures were approved by Institutional Animal Care
and Use Committees (at the University of Pennsylvania, the University of
Southern California, and the Pennington Biomedical Research Center)
and were performed according to the guidelines determined by the Na-
tional Institutes of Health. Rats had ad libitum access to rodent chow and
water unless otherwise noted.
Stereotaxic surgery
For behavioral experiments, rats were surgically implanted with cannula
targeting either the medial NTS (mNTS) or fourth cerebroventricle. Rats
were anesthetized with an intramuscular injection of ketamine (90 mg/
kg), xylazine (2.7 mg/kg), and acepromazine (0.64 mg/kg), and placed in
a stereotaxic apparatus. Guide cannulae (Plastics One; 26 gauge) were
implanted using the following coordinates: fourth cerebroventricle
(midline, 2.5 mm anterior to the occipital suture, internal cannula aimed
7.2 mm ventral to skull); and mNTS (bilateral cannula; 1.0 mm posterior
to occipital crest, 0.5 mm lateral to midline, internal cannula aimed 8.7
mm ventral to skull). Bone screws and dental cement adhered the can-
nula to the skull surface. Animals were treated with analgesia (2 mg/kg
meloxicam, s.c.) and were allowed 1 week to recover. Behavioral testing
began 14 d after surgery.
Fourth cerebroventricle cannula placements were verified before be-
havioral testing by assessing the hyperglycemic response to 5-thio-D-
glucose (210 g), as described previously (Hayes et al., 2009). mNTS
injection sites were confirmed anatomically following a postmortem in-
jection of 100 nl of pontamine sky blue. Only animals passing functional
or histological verifications were included in the final statistical analysis.
Immunohistochemical analyses
Detection and cellular localization of fluorescently labeled Ex-4. Rats were
injected with fluorophore-labeled Ex-4 (fluoro-Ex-4; AnaSpec) either in
the fourth cerebroventricle (0.3 g/1 l; maintained on chow ad libitum)
or intraperitoneally (10 g/ml/kg; given ad libitum access to chow, veg-
etable shortening, and 30% sucrose). This ligand has been shown to bind
to GLP-1R in cultured GLP-1R-expressing pancreatic  cells (Rajan et
al., 2015). Three hours after injection, rats were transcardially perfused
with 4% paraformaldehyde in PBS followed by cryoprotection in 20%
sucrose. This time point was selected based on previous research showing
that the anorectic effects of central Ex-4 do not develop until 3 h postad-
ministration (Hayes et al., 2011; Kanoski et al., 2011, 2012). Brains were
sectioned on a cryostat in the coronal plane at 30 m. Hindbrain sections
were collected at the level of the area postrema (from bregma, AP 13.6
to 14.2 mm). Briefly, sections were blocked in 0.1 M PBS containing 5%
normal donkey serum and 0.2% Triton-X at room temperature. Sections
were incubated in primary antibodies overnight, and then, following a
PBS rinse, they were incubated in secondary antibodies for 2 h. The
primary antibodies used were rabbit anti-NeuN (1:1000; ab177487, Ab-
cam) and goat anti-GFAP (1:1000; ab53554, Abcam). Secondary anti-
bodies (Jackson ImmunoResearch) were donkey anti-goat Alexa Fluor
594 (1:500) and donkey anti-rabbit 7-amino-4-methylcoumarin-3-
acetic acid (AMCA; 1:200; see Figs. 2, 4; Movie 1) or donkey anti-rabbit
Alexa Fluor 647 (1:500; see Fig. 3; Movie 2). Sections were visualized with
a Leica SP5 X confocal microscope using the 20 and 63 oil-
immersion objectives and the 405, 488, and 594 laser lines. Image z-stacks
with the 63 oil-immersion were collected with a step size of 1 m, while
2–3 optical zoom z-stack images using the same objective were col-
lected with a step size of 0.5 m. All images were collected sequentially to
avoid contamination of signals from other fluorophores. Three-
dimensional rotational animations were rendered from the collected
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z-stack images using Imaris 8.1.2 (Bitplane). To generate these anima-
tions, a Gaussian blur was first applied to the green channel (fluoro-Ex-4)
to smooth the background using default settings (filter size, 0.174 m).
For the blue channel (NeuN), a median filter (3  3  1 pixels) was
applied. Finally, the thresholds and gamma settings were adjusted [green:
thresholds, 4 – 40; gamma, 2.5; blue: thresholds, 2–90; gamma, 3; red
(GFAP): thresholds, 2–200; gamma, 1.2].
To evaluate whether the uptake of fluoro-Ex-4 into cells is mediated by
GLP-1R, separate rats were given a fourth cerebroventricle pretreatment
with either the competitive GLP-1R antagonist exendin-(9 –39) (Ex-9;
100 g; American Peptide) or vehicle [2 l of artificial CSF (aCSF; Har-
vard Apparatus)] 20 min before intraperitoneal injection of fluoro-Ex-4
(10 g/ml/kg). Rats were transcardially perfused 3 h later (4% parafor-
maldehyde in PBS followed by cryoprotection in 20% sucrose), and
brains were immunohistochemically processed for NeuN, GFAP, and the
fluorescently tagged Ex-4, as described above. Three-dimensional rota-
tional animations were generated for Ex-9-treated sections, as described
above. To evaluate colocalization of fluoro-Ex-4 in neurons and astro-
cytes from animals in each treatment group,
z-stacks were obtained from 63 with a 2–3
optical zoom (vehicle, 5 z-stacks from three an-
imals; Ex-9, 10 z-stacks from three animals),
and colocalization analysis was performed in
Imaris (version 7.6.5). The Gaussian filter was
applied to the green (fluoro-Ex-4) channel us-
ing default settings (0.175 m), the median fil-
ter was applied to the red (GFAP) and blue
(NeuN) channels (3  3  1 pixels), and an
additional Gaussian filter was applied to the
blue (NeuN) channel (0.175 m). The Imaris
Colocalization module was then run using
manual threshold settings (green, 4; red, 5;
blue, 2) to generate a colocalization channel
and statistics were exported. For each treat-
ment (vehicle or Ex-9), separate Pearson’s cor-
relation coefficients (PCCs) were generated for
colocalization of green and red (fluoro-Ex-4 in
astrocytes) and green and blue (fluoro-Ex-4 in
neurons).
Triple labeling of GLP-1/GFAP/synaptophy-
sin. Rats were perfused transcardially with
ice-cooled 0.9% saline, followed by 4% para-
formaldehyde in 0.1 M borate buffer at pH 9.5.
The brains were removed and immersed in
fresh fixative containing 12% sucrose for
20 –24 h at 4°C. The brains were then blocked
transversely at the level of the caudal midbrain,
and each block was flash frozen in dry ice-
cooled hexane before being sectioned frozen
on a sliding microtome (transverse plane, 30
m thickness, 5 series). Hindbrain sections
were collected at the level of the area postrema
(from bregma, AP 13.6 to 14.2 mm). Sec-
tions were stored in antifreeze solution at
20°C until further processing.
For simultaneous immunohistochemical
detection of GLP-1, GFAP, and synaptophysin,
all washes and incubations were completed at
room temperature, unless otherwise noted. All
primary and secondary antibodies were diluted
in a solution of potassium PBS (KPBS) con-
taining 2% donkey serum and 0.02% sodium
azide. Three primary antibodies (rabbit anti-
GLP-1, goat anti-GFAP, and mouse anti-
synaptophysin) were used for this study. For
each primary antibody used, a standard control
was performed in which the primary antibody
was omitted from the protocol (to control for a
nonspecific signal resulting from subsequent
antibody and signal detection reagents).
Tissue was washed with 0.02 M KPBS to remove antifreeze, and then
sections were permeabilized with 0.3% Triton X-100 in KPBS for 30 min.
After KPBS washes, the tissue went through a blocking step of 30 min in
2% normal donkey serum at room temperature. Tissue was incubated
overnight (18 h) at 2°C in rabbit anti-GLP-1 antibody (1:5000; T-4363,
Peninsula Laboratories). After KPBS washes, tissue was incubated for
48 h with goat anti-GFAP (1:500; ab53554, Abcam) and mouse anti-
synaptophysin (1:1000; 61012, PROGEN Biotechnik). Next, sections
were washed and then incubated overnight at 2°C in donkey anti-rabbit
secondary-Cy3 conjugate (1:500; Jackson ImmunoResearch), donkey
anti-goat secondary-AMCA conjugate (1:500; Jackson ImmunoRe-
search), and donkey anti-mouse secondary-AF488 conjugate (1:500;
Jackson ImmunoResearch). Sections were mounted onto glass slides and
coverslipped using 50% glycerol in KPBS mountant. Photomicrographs
were acquired as optical slices using a Zeiss LSM 700 UGRB confocal
system controlled by Zeiss Zen software.
Movie 1. Representative three-dimensional rotational video of fluoro-Ex-4 colocalization in NTS astro-
cytes and neurons following systemic administration of fluoro-Ex-4. Rats (n  2) were injected with
fluoro-Ex-4 peripherally (10 g/kg, i.p.) and killed 3 h later to label GLP-1R-expressing cells in the NTS. This
video is taken from a z-stack (0.5 m step size) collected from the mNTS at the level of the area postrema
with the 63 oil-immersion objective and a 2–3 optical zoom.
Movie 2. Internalization of systemically injected fluoro-Ex-4 in NTS cells is blocked by hindbrain pre-
treatment with a GLP-1R antagonist. Rats (n  4) received a fourth cerebroventricle injection of Ex-9 (100
g) followed 20 min later by injection of fluoro-Ex-4 (10 g/kg, i.p.). Three hours later, rats were killed to
visualize GLP-1R-expressing NTS cells. This three-dimensional rotational video is taken from a z-stack (0.5
m step size) from the mNTS at the level of the area postrema with the 63 oil-immersion objective and
2–3 optical zoom; a single image from this z-stack is shown in Figure 3B.
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Live cell calcium imaging
To prepare brainstem sections for live cell cal-
cium imaging experiments, the dyes Calcium
Green-1 AM (CG; Life Technologies) and sul-
forhodamine 101 (SR101; Invitrogen) were in-
jected into the NTS of rats (n  6), as
previously described (Hermann et al., 2009;
Vance et al., 2015). CAG is a calcium reporter
dye that labels both neurons and astrocytes,
while SR101 labels only astrocytes (McDougal
et al., 2011), allowing us to discriminate be-
tween astrocytes and neurons in our imaging
recordings. Cellular uptake of these dyes oc-
curred within 30 – 45 min. The anesthetized
rats were decapitated, and the brainstem was
quickly harvested. Prelabeled brainstem was
cut into coronal sections (300 m) on a vibrat-
ing microtome (VT1200, Leica) and sub-
merged in a cold (4°C) carbogenated (95%
O2/5% CO2) cutting solution (for detailed de-
scriptions, see Vance et al., 2015).
Live cell calcium imaging of prelabeled as-
trocytes and neurons was performed as previ-
ously described (Hermann et al., 2009; Vance
et al., 2015). Hindbrain slices were placed in and acclimated to the re-
cording chamber of a Nikon F1 fixed stage upright microscope with
constant exposure to Krebs’ recording solution. Each slice was exposed to
only one of two experimental designs. In one experiment, the slice was
exposed to 100 nM Ex-4 in the perfusion media for 80 s, and responses
were monitored for a minimum of 3 min. In the other experiment, the
slice was pretreated with the competitive GLP-1R antagonist Ex-9 (200
nM; Schepp et al., 1994) for 5 min; then exposed to Ex-4 for 80 s and
monitored for at least 3 min. For both designs, slices were then washed
out with normal Krebs’ solution for 10 min and next were stimulated by
exposure to Krebs’ recording solution containing 100 M ATP and 500
M L-glutamate for 80 s. This ATP/glutamate challenge was used as a
control to confirm that the neurons and astrocytes were viable and capa-
ble of producing calcium signals in response to experimental agonists.
Only those cells (astrocytes and neurons) that responded to the ATP/
glutamate challenge were included in the response analysis. Our previous
studies (Vance et al., 2015) have shown that response magnitudes of
neurons or astrocytes to ATP/glutamate do not decline even after multi-
ple exposures.
A Prairie Technologies (Bruker Corporation) line-scanning laser con-
focal head equipped with a Photometrics CoolSNAP HQ camera per-
formed time-lapse laser confocal calcium imaging. Nikon Elements AR
software was used to analyze the confocal live cell fluorescent signals in
the astrocytes and neurons as previously described (Hermann et al.,
2009; Vance et al., 2015). Individual astrocytes and neurons were desig-
nated as regions of interest (ROIs), and their fluorescence signal over
time was captured. Background fluorescence was subtracted from the
fluorescence signal. The relative changes in cytoplasmic calcium in the
cells were expressed as changes in fluorescence [(F/F )%], where F is
the intensity of the baseline fluorescence signal before stimulation, and
F is the difference between the peak fluorescence intensity and the
baseline signal. A minimum 5% change in fluorescence per cell was re-
quired to be included in analysis (McDougal et al., 2011).
Intracellular cAMP signaling response of immortalized medullary
rat astrocytes
Immortalized rat type-1 astrocyte DI-TNC1 cells (ATCC) were main-
tained at 37°C in 5% CO2 and were cultured in 1 DMEM with 4.5
mg/ml glucose (Invitrogen), 10% (v/v) fetal bovine serum (Thermo
Fisher Scientific), and 2% penicillin (10,000 IU/ml)-streptomycin
(10,000 g/ml) solution (Mediatech). Separate plates of DI-TNC1 cells
were treated with one of the following three GLP-1R agonists: GLP-1
(American Peptide); Ex-4 (American Peptide); or liraglutide (Bachem).
Three hour serum-starved DI-TNC1 astrocytes, cultured in a 96-well
culture plate (6  104 cells/well), were treated with three doses of each
agonist (0.1, 0.5, or 1.0 nmol; three plates per agonist/dose combination)
for 15 min. cAMP levels were calculated using a standard curve of fem-
tomoles of cAMP/10 4 DI-TNC1 cells. The same vehicle treatment (n  9
plates) was used for comparison with each GLP-1R agonist.
Feeding behavior
Comparison of fourth cerebroventricle Ex-4 versus fluorophore-labeled
Ex-4. Approximately 15 min before dark cycle onset, ad libitum-fed rats
(n  4) received an injection of Ex-4 (0.3 g, i.c.v.), fluorophore-labeled
Ex-4 (0.3 g, i.c.v.), or vehicle (aCSF; 1 l, i.c.v.). Doses of Ex-4 were
chosen based on the literature (Hayes et al., 2011), and each rat received
all treatments in a counterbalanced within-subjects design. At dark on-
set, rats were presented with preweighed chow, and intakes were re-
corded to the nearest 0.1 g at 1, 3, 6, and 24 h post-food presentation.
Body weights were recorded at 0 and 24 h after injection. Injections were
separated by a minimum of 72 h.
mNTS inhibition of astrocyte activity. Approximately 30 min before
dark cycle onset, ad libitum-fed rats (n  5) received a unilateral intra-
mNTS pretreatment of vehicle (100 nl of 0.1 M PBS) or the astrocyte
Krebs cycle inhibitor fluorocitrate (413 ng; DL-fluorocitric acid barium
salt, Sigma-Aldrich) followed by a second unilateral mNTS injection of
aCSF (100 nl) or Ex-4 (0.05 g) in a within-subject counterbalanced
design. At dark onset, rats were presented with preweighed chow, and
intakes were recorded to the nearest 0.1 g at 1, 3, 6, and 24 h post-food
presentation. Body weights were recorded at 0 and 24 h after injection,
and injections were separated by a minimum of 72 h.
Statistical analyses
Data for all experiments are expressed as the mean  SEM, with signifi-
cance set at p  0.05. To assess colocalization of fluoro-Ex-4 in NTS cells,
PCCs for the different fourth cerebroventricle drug conditions (vehicle
or Ex-9) were compared by separate two-tailed t tests for each cell type
(neurons or astrocytes). The PCC for astrocyte colocalization in one
z-stack from an Ex-9-treated animal was a statistical outlier (	2 SDs
from the mean) and that z-stack was eliminated from all statistical anal-
yses. In vitro cAMP data were analyzed by separate one-way ANOVAs,
followed by Dunnett’s post hoc analysis when the overall ANOVA was
significant. For calcium imaging studies, data were evaluated using the
Mann–Whitney U test. Results of the feeding studies were analyzed by
one-way or two-way mixed-design ANOVA, with drug condition as a
within-subjects factor, and comparisons between treatment groups were
made by Dunnett’s (fourth cerebroventricle) or Student–Newman–
Keuls (mNTS) post hoc tests. Analyses were performed using Statistica
12.0 or 13.0 (StatSoft).
Figure 1. Hindbrain administration of fluorescently labeled Ex-4 produces energy balance effects comparable to those of
unlabeled Ex-4. a, b, Fourth cerebroventricle administration of Ex-4 (0.3 g) reduces chow intake (a) and body weight gain (b) in
rats (n  4); an equal dose of fluoro-Ex-4 given at the fourth cerebroventricle causes similar suppression of feeding and body
weight gain. The key for a applies to both a and b. *p  0.05 compared with vehicle. Data are shown as the mean  SEM.
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Results
Astrocytes and neurons in the NTS express GLP-1 receptors
and internalize GLP-1R ligands
To provide anatomical evidence that GLP-1Rs are expressed on
astrocytes in the NTS, we tested the uptake of a fluorophore-
labeled version of the GLP-1R agonist exendin-4 (fluoro-Ex-4)
by neurons and astrocytes in the NTS, given the lack of a validated
commercially available GLP-1R-selective antibody. First, we ver-
ified that fluoro-Ex-4 has a comparable pharmacokinetic profile
of effect on food intake and body weight as an equal dose of
unlabeled Ex-4 when administered at the
fourth cerebroventricle in rats (Fig. 1;
feeding, F(2,6)  6.92, p  0.03; body
weight gain, F(2,6)  6.36, p  0.03; for
both feeding and body weight gain; vehi-
cle vs Ex-4 or fluoro-Ex-4, p  0.05; Ex-4
vs fluoro-Ex-4, p 	 0.05). Fluoro-Ex-4
was then injected at the fourth cere-
broventricle (0.3 g) or systemically (10
g/kg, i.p.), and the animals were tran-
scardially perfused 3 h later. The brains
were immunohistochemically processed
to label astrocytes and neurons, in con-
junction with visualization of fluoro-
Ex-4. Confocal microscopy revealed
colocalization of fluoro-Ex-4 in both
GFAP-positive astrocytes and NeuN-
positive neurons in the NTS following ei-
ther systemic or fourth cerebroventricle
delivery (Figs. 2, 4). Further, a three-
dimensional rotation video of 63
z-stack overlays within the NTS revealed
that systemically delivered fluoro-Ex-4
was internalized by both NTS astrocytes
and neurons (Movie 1). This movie avoids
the possibility of false overlaps that may
exist in the two-dimensional image (e.g.,
fluoro-Ex-4 directly in front of or behind
the cell may appear to be colocalized in a
two-dimensional image, but not in a three-dimensional
rotation).
To confirm that the binding and uptake of fluoro-Ex-4 in NTS
cells is mediated by GLP-1R, we tested whether internalization of
peripherally administered fluoro-Ex-4 would be attenuated by
pharmacological blockade of hindbrain GLP-1Rs. As shown in
Figure 3A, similar to our first study, fluoro-Ex-4 was colocalized
in both astrocytes and neurons in the NTS after fourth cere-
broventricle pretreatment with vehicle (2 l). However, hind-
brain injection of the competitive GLP-1R antagonist Ex-9 (100
Figure 3. The internalization of peripherally administered fluoro-Ex-4 in NTS cells is blocked by fourth cerebroventricle pre-
treatment with a GLP-1R antagonist. A, B, While uptake of fluoro-Ex-4 (10 g/kg, i.p.) was observed in NTS astrocytes and neurons
of rats given a fourth cerebroventricle pretreatment with vehicle (A; n  3), central pretreatment with Ex-9 (100 g) blocked this
effect (B; n  4; see also Movie 2). Fluoro-Ex-4 is shown in green, GFAP-positive cells are shown in red, and NeuN-positive neurons
are shown in blue. The smaller insets at the top of each panel depict representative NTS-containing coronal sections at 20
magnification. The boxed area of each inset was magnified to 63 and a further 2–3 optical zoom was applied to generate the
large images. cc, Central canal.
Figure 2. Fluorescently labeled Ex-4 is taken up by neurons and astrocytes within the NTS following systemic administration. Rats (n  2) were injected with fluoro-Ex-4 peripherally (10 g/kg,
i.p.) and transcardially perfused 3 h later. A representative NTS-containing section is shown at 20 magnification in A, with GFAP-positive cells shown in red and NeuN-positive cells in blue. The
dotted box outlined in A is magnified in B. This higher-magnification image in B depicts a single image within a z-stack (0.5 m step size) taken with the 63 oil-immersion objective shows
fluoro-Ex-4 labeling in GFAP-positive cells (red) and NeuN-positive cells (blue). White arrows indicate cells lacking colocalization with fluoro-Ex-4, while yellow arrows indicate cells that take up
fluoro-Ex-4. The dotted box in B indicates the field of view in Movie 1. cc, Central canal.
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g) blocked the uptake of fluoro-Ex-4 in NTS cells (Fig. 3B;
Movie 2, three-dimensional rotational video). Quantitative anal-
yses suggest that Ex-9 pretreatment blocks colocalization of
fluoro-Ex-4 in both astrocytes (vehicle, r  0.20  0.12; Ex-9, r 
0.07  0.03; t(12)  2.75, p  0.02) and neurons (vehicle, r 
0.23  0.10; Ex-9, r  0.03  0.04; t(12)  2.36, p  0.04).
Although this analysis does not account for the location of the
fluoro-Ex-4 (e.g., on the cell surface vs internalized), as Ex-9 is a
competitive GLP-1R antagonist, it would likely block both recep-
tor binding and internalization of the agonist. Collectively, these
data provide further evidence that uptake of the fluorescently
tagged Ex-4, like untagged Ex-4, is mediated by the GLP-1R.
Again, the inclusion of Movie 2 avoids the potential for false
overlaps in the two-dimensional image in Figure 3B.
These data provide novel anatomical evidence suggesting that
astrocytes bind and take up GLP-1R ligands; these results also
show that a peripherally injected GLP-1R agonist can penetrate
the blood– brain barrier and gain access to the NTS. Further-
more, these data show that a portion of astrocytes and neurons do
not take up the fluoro-Ex-4, suggesting that these cells do not
express the GLP-1R, while other cells in adjacent proximity show
clear uptake of the fluoro-Ex-4 and putatively express GLP-1Rs
(shown explicitly in Fig. 2).
NTS astrocytes and neurons show increased live cell calcium
signaling following Ex-4-induced GLP-1R activation
To test the ability of astrocytes in the NTS to respond to GLP-1R
activation, ex vivo live cell calcium signaling in NTS-containing rat
brainstem slices was evaluated following bath application of Ex-4
(100 nM). Astrocytes were prelabeled with the astrocyte-specific dye
SR101, and both astrocytes and neurons were prelabeled with the
calcium-sensitive dye CG (Fig. 5A–C). An increase in intracellular
calcium corresponded to an increase in fluorescence and is indica-
tive of cellular activation (Rogers et al., 2006). In viability experi-
ments, ATP/glutamate stimulation activated 129 NTS astrocytes
with a mean magnitude of increased fluorescence of 24.6  1.2%
(Fig. 5D,F,G). Of the 129 NTS astrocytes responsive to the ATP/
glutamate challenge, 40% were also directly responsive to Ex-4 stim-
ulation (Fig. 5E,F) with a 20.1  4.2% mean magnitude of response
(Fig. 5G), which is similar in magnitude to the response to ATP/
glutamate. A similar proportion of NTS neurons was responsive to
Ex-4 stimulation (14 of 38 ATP/glutamate-responsive neurons; Fig.
5E,F). Those neurons that were responsive to both stimuli averaged
lower magnitudes in their response to Ex-4 relative to their evoked
response to ATP/glutamate (Fig. 5H).
In separate hindbrain slices, pre-exposure to the competitive
GLP-1R antagonist Ex-9 reduced the overall number of Ex-4-
responsive astrocytes from 40% to 20% (Fig. 5F). NTS astro-
cytes that were still activated by Ex-4 following Ex-9 pre-exposure
had a significantly diminished response to Ex-4 (Fig. 5G; U  37,
p  0.0002). In contrast, while Ex-9 suppressed the number of
NTS neurons responsive to Ex-4 from 37% to 13% (Fig. 5F),
the magnitude of their response to Ex-4 was not further inhibited
by Ex-9 (Fig. 5H; U  20, p  0.53).
Figure 4. Fluorescently labeled Ex-4 is taken up by neurons and astrocytes within the NTS
following fourth cerebroventricle administration. Rats (n  3) were injected with fluoro-Ex-4
(0.3 g, i.c.v.) and killed 3 h later. A, B, A representative NTS-containing brain section is shown
at 20 magnification in A, with GFAP-positive cells shown in red and NeuN-positive cells in
blue. The dotted box outlined in A is magnified in B. This higher-magnification image in B
shows a single image within a z-stack (1 m step size) taken with the 63 oil-immersion
objective and depicts fluoro-Ex-4 labeling in GFAP-positive cells (red) and NeuN-positive cells
(blue). The dotted rectangle indicates the location of an additional 2–3 optical zoom repre-
sented in C within the same z-stack (0.5 m step size). cc, Central canal.
Figure 5. GLP-1R activation increases calcium signaling in subsets of both NTS astrocytes and
neurons. A–C, NTS cells (n6 rats) were preloaded with CalciumGreen-1 AM (calcium-sensitive dye;
labels astrocytes and neurons) and SR101 (astrocyte-specific red dye); yellow colocalization confirms
that the calcium-sensitive dye is localized in astrocytes. Astrocytes and neurons are designated as a
ROI; red, neuron; blue, astrocyte. Calcium-induced changes in fluorescence in response to perfusion
parameters are quantitated over time. The percentage change in fluorescence for each ROI over time
is shown in corresponding line colors (neuron in red, astrocyte in blue). Control (viability) experiments
were performed (representative traces in D) in which a cocktail of ATP/glutamate was applied for 80 s
to identify viable, responsive astrocytes and neurons (i.e., increased intracellular calcium as demon-
strated by increased fluorescence). The increase in intracellular calcium is immediate due to the com-
bined opening of ligand-gated cation channels and the intracellular release of stored calcium. E, F,
Approximately 40% of NTS astrocytes and neurons was also activated by GLP-1R agonist Ex-4 (repre-
sentative traces in E, quantification of cells in F ). Pre-exposure of the slice to the competitive GLP-1R
antagonist Ex-9 reduces the number of Ex-4-responsive cells to 20% (F ). G, The subpopulation of
NTS astrocytes activated by Ex-4 exhibits a similar magnitude of calcium response as that elicited by
the ATP/glutamate cocktail, but pre-exposure to Ex-9 reduces the magnitude of this response. H, In
contrast, the magnitude of the calcium response in neurons to Ex-4 was not further inhibited by Ex-9.
For G and H, data are shown as the mean  SEM *p  0.05.
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GLP-1R activation increases cAMP in astrocytes in vitro
Downstream intracellular signaling events of GLP-1R activation
in neurons include elevated levels of cAMP and protein kinase A,
which are required for the anorexigenic effects of GLP-1R activa-
tion (Hayes et al., 2011). However, it is unknown whether this
signaling pathway is also recruited by astrocytic GLP-1R activa-
tion. To determine whether GLP-1R activation increases cAMP
levels specifically in astrocytes, we measured cAMP concentra-
tion in an immortalized rat type-1 astrocyte cell line (DI-TNC1)
after exposure to one of three GLP-1R agonists [GLP-1(7–36),
exendin-4 (Ex-4), or liraglutide; 0.1, 0.5, 1.0 nmol]. These in vitro
analyses demonstrated that each of the three GLP-1R ligands caused
a significant dose-dependent increase in cAMP concentrations in
astrocytes (Fig. 6; GLP-1: F(3,14) 3.74, p0.04; Ex-4: F(3,14) 6.02,
p  0.01; liraglutide: F(3,14)  6.12, p  0.01). These data suggest
that, like the cAMP responses previously observed in neurons
(Hayes et al., 2011), cAMP signaling is engaged downstream of
GLP-1R activation in astrocytes.
Endogenous GLP-1-immunopositive fibers form synaptic
contact with NTS astrocytes
To provide evidence of a potential endogenous source of GLP-1 to
NTS astrocytes, immunohistochemical triple labeling was
performed to identify GLP-1 axons, astrocytes (GFAP immunopo-
sitive), and presynaptic terminals (synaptophysin immunopositive)
in the NTS of rats. As shown in Figure 7, GLP-1 and synaptophysin
colocalized in NTS GFAP-positive astrocytes, indicating that GLP-1
axons terminate in close apposition (presumably synaptic contacts)
to NTS GFAP-positive astrocytes. These anatomical data suggest
that NTS PPG neurons are a putative endogenous source of GLP-1
to NTS astrocytes.
Astrocytes mediate the food intake- and body weight-
suppressive effects of GLP-1R activation in the NTS
To test whether NTS astrocytes play a role in the energy balance
effects of GLP-1R activation, food intake and body weight gain
were measured in rats following NTS-targeted treatment with the
astrocyte Krebs cycle inhibitor fluorocitrate (413 ng; Lian and
Stringer, 2004; Hermann et al., 2014) and Ex-4 (0.05 g). As
shown in Figure 8, NTS pretreatment with fluorocitrate attenu-
ated both the hypophagia and body weight reduction produced
by direct NTS administration of Ex-4 [24 h food intake: interac-
tion between fluorocitrate and Ex-4, F(1,4)  10.08, p  0.03;
body weight: F(1,4)  33.87, p  0.004; for both 24 h food intake
and body weight, vehicle/vehicle vs vehicle/Ex-4, p  0.05;
vehicle/Ex-4 vs fluorocitrate/Ex-4, p 
0.05; no statistically significant interac-
tion between fluorocitrate and Ex-4 at 1,
3, or 6 h (all F(1,4) 1.04, all p  0.37; data
not shown)]. These findings suggest that
inhibiting astrocyte activity attenuates the
ability of NTS GLP-1R activation to pro-
mote negative energy balance.
Discussion
Astrocytes play a critical role in regulating
glutamatergic neurotransmission, yet are
surprisingly understudied as potential
mediators of energy balance-relevant sig-
nals. Given that the food intake- and body
weight-suppressive effects of central
GLP-1R signaling are mediated in part by
presynaptic modulation of glutamate sig-
naling (Hisadome et al., 2011; Mietlicki-
Baase et al., 2013, 2014), it is intriguing to consider the idea that
GLP-1Rs expressed on astrocytes may influence glutamate sig-
naling to affect energy balance. We focused our attention on
astrocytes in the NTS because of the critical role this nucleus
serves in processing vagally mediated glutamatergic satiation sig-
nals (Grill and Hayes, 2012), as well as the endogenous relevance of
NTS GLP-1R signaling for the control of feeding (Hayes et al., 2009).
Novel data presented here show the following: (1) that astrocytes are
activated by GLP-1 and GLP-1R agonists; (2) that the GLP-1R ago-
nist Ex-4 is internalized by and produces robust calcium signaling in
NTS neurons and astrocytes; (3) that endogenous central GLP-1
neurons form close synaptic appositions with NTS astrocytes; and
(4) that NTS astrocyte activity is required for the hypophagia and
reduction in body weight produced by NTS GLP-1R activation.
Unlike the short half-life of endogenous peripheral GLP-1, sys-
temically administered GLP-1R agonists Ex-4 and liraglutide are re-
sistant to degradation by dipeptidyl peptidase-4 and thus remain in
circulation for longer periods of time to impact energy balance
(Kanoski et al., 2011; Secher et al., 2014; Sisley et al., 2014). These
drugs are used clinically for the treatment of T2DM, and more re-
cently, liraglutide also has been approved by the FDA for the treat-
ment of obesity (Tella and Rendell, 2015), highlighting the
importance of fully understanding the mechanisms by which these
GLP-1R agonists exert their metabolic effects. To address the ability
of GLP-1R agonists to activate NTS astrocytes, an important first
step was to confirm GLP-1R expression on astrocytes. Given the lack
of a validated commercially available GLP-1R-selective antibody, we
instead availed ourselves of a novel use of fluorophore-tagged Ex-4
and tested its ability to label GLP-1R-expressing cells in the NTS.
Injection of fluoro-Ex-4 either centrally or peripherally revealed that
some, but not all, NTS astrocytes and neurons were labeled with the
fluorescent tag, indicating binding of the ligand and thus probable
GLP-1R expression. The finding that uptake of peripherally admin-
istered fluoro-Ex-4 was blocked by hindbrain pretreatment with
Ex-9 further supports GLP-1R mediation of these effects. These re-
sults also provide visual evidence that this long-lasting GLP-1R ago-
nist can cross the blood–brain barrier and bind to receptors within
the CNS. Perhaps most intriguing is the discovery that fluoro-Ex-4
was internalized not only by neurons (Secher et al., 2014), but also by
astrocytes. Unsurprisingly, there was more robust fluoro-Ex-4 label-
ing on NTS neurons and astrocytes when the drug was injected at the
fourth cerebroventricle compared with peripheral injection. It is
possible that this effect is due not just to the concentration of the
localized injection, but may also be a secondary consequence of in-
Figure 6. GLP-1R activation increases cAMP concentration in astrocytes in vitro. A–C, Bath application of the GLP-1R agonists
GLP-1 (A), Ex-4 (B), or liraglutide (C) elevated cAMP levels in immortalized rat type-1 astrocytes (DI-TNC1). For each agonist/dose
combination, n  3 plates of cells; for control, n  9 plates of cells. Data shown as the mean  SEM. *p  0.05; #p  0.08
compared with control (dose 0).
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creased GLP-1R expression in glia following
fourth cerebroventricle surgery (Chowen et
al., 1999). Thus, there is a clear need for fu-
ture dose–response and time-course exper-
iments to fully evaluate the penetrance and
uptake of fluoro-Ex-4 throughout the CNS
following both systemic and central
injections.
A combination of in vitro and ex vivo
approaches was used to demonstrate that
astrocytes not only internalize a GLP-1R
agonist, but also are responsive to GLP-1R
activation. Ex vivo live cell calcium imag-
ing data indicated that subpopulations of
astrocytes and neurons within the NTS
are responsive to GLP-1R activation. Ap-
proximately 40% of all viable NTS astro-
cytes and neurons also responded to Ex-4.
However, pre-exposure of the slice to
Ex-9 reduced the numbers of NTS astro-
cytes and neurons responding to Ex-4.
Furthermore, the magnitude of the NTS
astrocyte response to Ex-4 was reduced
by Ex-9; in contrast, Ex-9 pretreatment
did not further blunt the magnitude of
response to Ex-4 in neurons that remained responsive. This
observation opens the possibility that NTS neuron responses
to Ex-4 may be activated, at least in part, by an indirect
gliotransmission-driven pathway following GLP-1R activa-
tion of astrocytes.
To directly examine whether GLP-1R-mediated calcium
signaling engages cAMP as a second messenger in astrocytes,
an immortalized rat type-1 astrocyte DI-TNC1 cell line was
used. Similar to the response previously observed in neuronal
cultures (Hayes et al., 2011), cAMP levels increased dose de-
pendently in the astrocyte cell line following activation by any
one of three GLP-1R agonists tested (GLP-1, Ex-4, or liraglu-
tide). These data suggest that GLP-1R activation and recruit-
ment of the appropriate intracellular signaling cascades occur
not only in neurons but also in astrocytes.
Previous research has shown that endogenous NTS GLP-1R sig-
naling is physiologically relevant for food intake control, as blockade
of endogenous NTS GLP-1R by hindbrain administration of Ex-9
leads to a significant increase in food intake (Hayes et al., 2009).
However, it is unknown whether this effect is due to blockade of
GLP-1R expressed on NTS neurons, astrocytes, and/or vagal afferent
terminals. Given that NTS PPG neurons synthesize GLP-1, endoge-
nous GLP-1 produced within the NTS could engage astrocytes for
energy balance control. Indeed, the novel immunohistochemical
analyses presented here provide anatomical evidence that endoge-
nous GLP-1 axons make close appositions with NTS astrocytes. This
finding does not establish whether these points of contact are classic
“synapses,” and it remains unclear whether true synaptic communi-
cation occurs at these apposed membranes or whether the GLP-1
axons and NTS astrocytes interact in some other way. Nevertheless,
Figure 7. GLP-1-containing axons form close appositions with NTS astrocytes. Representative 1.5-m-thick images from NTS-containing transverse sections (n  3 rats) show GLP-1 in red,
GFAP (astrocyte marker) in blue, and synaptophysin in green. White arrows indicate triple labeling, providing evidence for synaptic-like contacts between GLP-1-containing cells and astrocytes in
the NTS. The top orthogonal in A represents the x–z plane for the z-stack, whereas the right orthogonal represents the y–z plane for the z-stack. The cross hairs in this panel (red vertical line meets
green horizontal line) highlight one of several examples of three-label evidence for appositions at this level of the NTS. The inset in B reveals this at higher resolution, with the three-label example
at the cross hairs in A represented by the top arrow in B. AP, Area postrema.
Figure 8. Inhibition of mNTS astrocytes attenuates the food intake- and body weight-suppressive effects of mNTS GLP-1R
activation. Rats (n  5) were given an intra-mNTS pretreatment with the astrocyte Krebs cycle inhibitor fluorocitrate or its vehicle,
followed by direct mNTS administration of the GLP-1R agonist Ex-4. A, B, Fluorocitrate, at a dose that on its own had no effect on
chow intake or body weight gain, significantly attenuated the ability of intra-mNTS Ex-4 to reduce chow intake (A) and body
weight gain (B) over the 24 h postinjection. *Significantly different from vehicle/vehicle ( p  0.05); T p  0.05 vs vehicle/Ex-4.
Key applies to both panels. Data are shown as the mean  SEM.
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these close appositions suggest an interaction between the GLP-1-
producing neurons and astrocytes, and future studies are warranted
to examine the contribution of endogenous, astrocyte-specific
GLP-1R signaling for energy balance control.
Behavioral food intake and body weight analyses demonstrated
that inhibition of NTS astrocyte metabolic function with fluoroci-
trate attenuated the intake and body weight suppression produced
by NTS GLP-1R activation. This finding supports the hypothesis
that NTS astrocytes not only bind, internalize, and display appropri-
ate signaling responses to GLP-1R agonists, but also that NTS astro-
cytes mediate the energy balance effects of GLP-1R signaling.
Fluorocitrate inhibits glial cells by blocking aconitase activity,
thereby disrupting the tricarboxylic acid cycle (Peters, 1957; Brand et
al., 1973; Fonnum et al., 1997). Although multiple types of glia can be
inhibited by fluorocitrate, it appears to have the most potent effects
on astrocytes (Paulsen et al., 1987). Any potential influence of oligo-
dendrocytes or microglia on the behavioral effects observed in this
experiment would likely be minimal compared with astrocytic con-
tributions, but this possibility cannot be ruled out. At very high
doses, fluorocitrate can also disrupt neuronal activity (Koenig,
1969), but the dose used in our study (413 ng or 0.5 nmol) is far
below subthreshold concentrations for neuronal effects (Paulsen et
al., 1987; Hassel et al., 1992; Willoughby et al., 2003).
As fluorocitrate blocks all astrocyte activity, it is impossible to
tease apart the exact role of astrocytes in mediating GLP-1R intake
suppression by this pharmacological manipulation. For example, we
cannot definitively exclude the possibility that astrocytes are indi-
rectly involved with the behavioral effects of GLP-1R activation.
That is, NTS fluorocitrate injection will nonselectively inhibit all
NTS astrocytes, not only GLP-1R-expressing astrocytes, so one can-
not rule out the alternative explanation that astrocytes are engaged
along with or even downstream of neuronal GLP-1R activation, or
that non-GLP-1R-expressing astrocytes may play some indirect role
in these anorexic effects. However, the results of the calcium imaging
studies argue against these possibilities. The near-simultaneous acti-
vation of NTS astrocytes and neurons by Ex-4 in that experiment
supports the hypothesis that Ex-4 acts directly on at least a subset of
NTS astrocytes. Even if GLP-1R activation in these astrocytes ac-
companies neuronal GLP-1R activation, our behavioral data suggest
that astrocytes are required for the control of energy balance by NTS
GLP-1R activation.
An important empirical question arising from these studies is the
mechanism by which astrocytic GLP-1R activation might alter glu-
tamatergic neurotransmission to affect energy balance. Increased
cAMP levels have been linked to reduced expression of glutamate
transporters (Lim et al., 2005). Our data demonstrating that astro-
cytic GLP-1R activation elevates cAMP hints at the intriguing possi-
bility that astrocytic glutamate transporters (e.g., GLT-1, GLAST)
may be downregulated as a result of GLP-1R activation, providing a
potential mechanism by which GLP-1R signaling in astrocytes could
increase glutamate levels in the NTS synapse and consequently re-
duce food intake (Ritter, 2004; Hisadome et al., 2011; Mietlicki-
Baase et al., 2013, 2014). GLP-1R activation also increases
interleukin signaling (Shirazi et al., 2013). As interleukins can block
the ability of astrocytes to take up glutamate from the synapse (Taka-
hashi et al., 2003), this offers an additional possible mechanism by
which astrocytic GLP-1R activation may alter synaptic glutamatergic
signaling. Interestingly, cytokines can also sensitize vagal afferent
signaling (Hermann and Rogers, 2008). Thus, NTS GLP-1R activa-
tion, including activation of receptors on astrocytes, may directly
inhibit glutamate reuptake and engage cytokine signaling to enhance
synaptic glutamate levels, while simultaneously enhancing incoming
vagal neurotransmission to affect subsequent feeding behavior.
Collectively, the current data show that NTS astrocytes are en-
gaged by GLP-1R activation to control energy balance. Central acti-
vation of GLP-1R in a variety of nuclei has a broad range of
behavioral and physiological effects. In addition to the NTS, several
nuclei within the brain mediate the hypophagic effects of GLP-1
(Hayes et al., 2014). Additionally, CNS GLP-1R mediate diverse phe-
nomena including glycemic control (Sandoval et al., 2008), moti-
vated behavior (Harasta et al., 2015), and even presumably
protection against neurodegeneration (Bao et al., 2015). The possi-
bility that astrocytic GLP-1R activation contributes to these effects is
just beginning to be considered. As FDA-approved drugs such as
Ex-4 and liraglutide target the central GLP-1 system, the present
findings may also be of clinical significance as the scientific commu-
nity strives to comprehend more fully the mechanisms by which
GLP-1R agonists exert their physiological and behavioral effects. In
summary, the current findings not only demonstrate the importance
of NTS astrocytic GLP-1R signaling for food intake control, but also
represent the beginning of an enormous opportunity for deeper un-
derstanding of the mechanisms by which central GLP-1 signaling
influences physiology and behavior.
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